by Raynovich Rod | Dec 19, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Macro
Biotech Stocks Rally to New Highs After 4% Correction Buyers Are Bottom Feeding Energy Stocks NASDAQ at 4765 Just as the market appeared to be headed to another test of October lows, challenged by news on slowing global growth and a collapsing energy sector, FED Chair...
by Raynovich Rod | Dec 15, 2014 | Biopharmaceuticals
December 18 “Don’t Fight the Fed”-cliches still work. Biotechs roar back near YTD highs. Yellen calms volatile markets. Healthcare Stocks Not Immune To Bearish Mood Crude Hits Lowest Level in Five Years Biotech stocks joined the market sell-off...
by Raynovich Rod | Dec 11, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Part 1 Biopharmaceutical Stocks-New Highs Were Hit on December 10 Five Straight Years of Gains in Biotech-the IBB is up 292% since Dec 18, 2009 Biotech stocks are following the long term seasonal bullish trend surging in Q4 and up about 49 % YTD. The easiest way to...
by Raynovich Rod | Dec 10, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Macro
Crude Trade Roils Markets-But Biotech Is Still A Safe Haven Second Worst Week of the Year-Late Day Trading Hit By Selling As the market becomes more volatile we should look at how the energy trade is affecting other asset classes. Certainly materials and industrials...
by Raynovich Rod | Dec 1, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Bounce Back Day 12/2/14 FBT up 1.5% to $102.33 Biotech players realized that news about China, energy and holiday shopping data do not affect their stocks. Our large cap biopharma portfolio went green helped by Biogen Idec (BIIB) up 6.43% on Phase 1a data for an...
by Raynovich Rod | Nov 26, 2014 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
NASDAQ leads -up 0.6% to 4787 The October correction of ~7% was a “headfake” as macro events scared many investor away Technology and Healthcare Stocks Lead The Way The healthcare SPDR (XLV) is up 24.5% YTD and the technology SPDR (XLK) is up 18% YTD....
by Raynovich Rod | Nov 14, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Red Tape Today Means Caution-Take Some Off XBI at $167.83 Off 2% Traders, investors, executives even pension funds are thrilled with biotech investing as the stock group rolls on to new highs this month. What may not be appreciated is the 20% move off the October 16...
by Raynovich Rod | Oct 31, 2014 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Investors Whipsawed By V-Shaped Rally NASDAQ at New Highs 4631 DOW at New Highs 17,390 Investors got what was forecasted-a volatile October that moved from fear to greed in two weeks! The market was buffeted by the Ebola scare, macro analysts decrying easy money from...
by Raynovich Rod | Oct 23, 2014 | Biopharmaceuticals
Genetically Modified T-cells: Gene Therapy Is Back! Here are some quick notes and an overview of the companies at Bio: Immuno-Oncology is one of the hottest new areas of biopharmaceutical development and on October 7 BIO presented a Therapeutic Session on...
by Raynovich Rod | Oct 20, 2014 | Biopharmaceuticals, Clinical Diagnostics and Tools, Life Science ETF's and Mutual Funds
Biotechs Continue To Lead The Market NASDAQ registered its third day of gains up 2.38% for the period and life science stocks followed. The NAZ is now up 3.34% YTD. Biotech stocks are way ahead of the market YTD with our top ETF pick (FBT) up 31% YTD and 3.66% over...
